

Fixed vs. Weight-based Prothrombin Complex Concentrate for Factor Xa Inhibitor Reversal in Patients with Intracranial Hemorrhage

Elizabeth Overmiller, PharmD¹; Madison Waddell, PharmD²; Leah Lofquist, PharmD³; Natalia Fijas, PharmD⁴; Kaelin Randle, PharmD⁵; Samiha Badwan, PharmD³; Kendall H Brickel, PharmD, BCPS⁵; Katie E Dalton, PharmD, BCCCP⁵; Bayar Haji, PharmD, BCPS²; Stacie Kroboth, BS⁶; Megan Robbins Laux, PharmD, BCPS²; Monika Obsto, PharmD, BCCCP⁴; Emilia Szczesniak-Lagowski, PharmD⁴; Hailey Sullivan, PharmD, BCPS¹; Angela Zivkovic, PharmD, BCCCP³; Erica N Presnell, PharmD, BCCCP¹

- 1 Ascension Via Christi Hospitals Wichita, Inc, 929 N St. Francis, Wichita, KS, 67214
- 2 Ascension Saint Thomas Hospital Midtown, 2000 Church St, Nashville, TN 37203
- 3 Ascension All Saints Hospital, 3801 Spring St, Racine, WI 53405
- 4 Ascension Alexian Brothers, 800 Biesterfield Rd, Elk Grove Village, IL 60007
- 5 Dell Seton Medical Center at the University of Texas, 1500 Red River St, Austin, TX 78701
- 6 Ascension Data Science Institute, Ascension Health, St. Louis, Missouri

Table of Contents

Supplemental Table 1:.....	Page 2
Supplemental Table 2:.....	Page 3
Supplemental Table 3:.....	Page 4
Supplemental Table 4:.....	Page 5-6

Market	4F-PCC Dose for FXaI reversal
Illinois [^]	25 units/kg Max of 2000 units for FXaI
Kansas	2000 units 50 units/kg prior to July 2024
Tennessee	Providers choice
Texas	50 units/kg 25-50 units/kg prior to June 2025
Wisconsin [^]	2000 units

Supplemental Table 1: Facility specific 4F-PCC, Four-Factor Prothrombin Complex Concentrate Dose for FXaI reversal

[^] denotes facility locations that utilize Factor IX component on box

FXaI, Factor Xa Inhibitor; 4F-PCC, Four-Factor Prothrombin Complex Concentrate

Characteristic	Fixed Group (n=250)	Weight-Based Group (n=336)
HIT during index encounter	0 (0)	2 (0.6)
PMH refusal of blood products	1 (0.4)	5 (1.5)
Refusal of blood products during index encounter	2 (0.8)	2 (0.6)
Additional reversal agents		
Phytonadione	16 (6.4)	17 (5.1)
TXA	5 (2)	5 (1.5)
Cryoprecipitate†	3 (1.2)	0 (0)
FFP	6 (2.4)	15 (4.5)
Protamine	3 (1.2)	3 (0.9)
Recombinant Factor VIIa	0	0
Desmopressin	4 (1.6)	4 (1.19)

Supplemental Table 2: Additional baseline characteristics

Data presented as numbers (%), unless otherwise stated

† Denotes statistical significance with p-value <0.05

HIT, heparin induced thrombocytopenia; PMH, past medical history; TXA, tranexamic acid; FFP, fresh frozen plasma

	Fixed (n=250)	Weight-Based (n=336)
Illinois	63 (25.2)	25 (7.4)
Kansas	38 (15.2)	100 (29.8)
Tennessee	8 (3.2)	97 (28.9)
Texas	38 (15.2)	109 (32.4)
Wisconsin	103 (41.2)	5 (1.5)

Supplemental Table 3: Included patients based on state location
Data presented as numbers (%)

Characteristic	Effective Hemostasis (n=372)	No hemostasis (n=214)
Age, Median (IQR)	77.2 (69.46-84.03)	77.8255 (71.293-84.507)
Sex, male	213	124
Weight, kg - Median (IQR)	81.095 (70.307-95.6)	78.718 (64.824-98.892)
BMI, Median (IQR)	27.6 (23.975-32.5) n=370	26.8 (23.4-32.050) n=209
Race		
Caucasian	312	177
African American	38	19
Hispanic	3	2
Other	13	15
Unknown	6	1
Medical history		
Atrial Fibrillation	282	172
VTE	105	55
Factor V Leiden	0	0
Protein C or S Deficiency	2	0
APS†	0	1
HLD	222	126
HTN	268	150
CAD†	114	78
HF	100	52
DM	124	73
Ischemic Stroke	85	54
HIT	1	0
HIT during index encounter	1	1
PMH Refusal of blood products†	2	4
Refusal of blood products during index encounter†	4	0
Antiplatelet use prior to arrival (%)		
P2Y12 Inhibitor		
Clopidogrel	23	17
Prasugrel	3	1
Ticagrelor†	3	0
Aspirin	116	59
Dipyridamole	1	1
Cilostazol	0	0
Anticoagulation prior to arrival		
Apixaban	272	156
Rivaroxaban	100	58
Type of ICH		
Traumatic	178	104
Non-traumatic	194	110
Location of ICH		
Intracerebral†	248	154
Subdural†	76	61
Epidural†	0	2
Subarachnoid	134	88
Intraventricular†	30	46
Other	1	1
Additional reversal agents		
Phytonadione†	15	18

TXA†	3	7
Cryoprecipitate	1	2
FFP	12	9
Protamine	3	3
Recombinant Factor VIIa	0	0
Desmopressin†	3	5
Fixed Dosing†	171	79

Supplemental Table 4: Multivariate logistic regression baseline characteristics comparing effective hemostasis vs no hemostasis.

Data presented as numbers (%), unless otherwise stated

† Denotes statistical significance with p-value <0.2

IQR, interquartile range; Kg, kilograms; BMI, Body Mass Index; VTE, venous thromboembolism; APS, antiphospholipid syndrome; HLD, hyperlipidemia; HTN, hypertension; CAD, coronary artery disease; HF, heart failure; DM, diabetes mellitus; HIT, heparin induced thrombocytopenia; PMH, past medical history; ICH, intracranial hemorrhage; TXA, tranexamic acid; FFP, fresh frozen plasma